



GLOBAL JOURNAL OF MEDICAL RESEARCH: B
PHARMA, DRUG DISCOVERY, TOXICOLOGY & MEDICINE
Volume 16 Issue 1 Version 1.0 Year 2016
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals Inc. (USA)
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Design, Synthesis, Spectral Characterization of Some New Fully Unsaturated 2-Substituted-4,6 Dichloro Symmetric Triazine- based Chalcone Hybrids

By G. V. Pavan Kumar, D. Srinivasa Rao, B. Pooja, G. Harika & Y. Anil Kumar

Kc Reddy Institute of Pharmaceutical Sciences, India

Abstract- Triazines and chalcones are interesting class of heterocyclic compounds with a prominent structural core system present in numerous pharmacologically active compounds. It is proved from the literature that the compounds containing 1,3,5-triazine moiety or chalcone bridge often shows significant biological activity profiles. Based on these observations, it was considered worthwhile to synthesize and characterize some new 1,3,5-triazine-chalcone hybrid molecules in the present investigation. As a part of our research program aimed at search for new hybrid pharmacophores as potential cytotoxic agents, we are interested to have α,β -unsaturated ketone linker to the 1,3,5-triazine basic nucleus to give a series of 1,3,5-triazine-chalcone hybrid molecules. Therefore, in the present study an attempt has been made to synthesize and characterize various analogs of fully unsaturated 2-substituted-4,6 dichloro-1,3,5 triazine based chalcone hybrids.

Keywords: *fully unsaturated, 1,3,5-triazine-chalcone hybrids, spectral characterization.*

GJMR-B Classification : *NLMC Code: QV 4*



Strictly as per the compliance and regulations of:



© 2016. G. V. Pavan Kumar, D. Srinivasa Rao, B. Pooja, G. Harika & Y. Anil Kumar. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License <http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Design, Synthesis, Spectral Characterization of Some New Fully Unsaturated 2-Substituted-4,6 Dichloro Symmetric Triazine- based Chalcone Hybrids

G. V. Pavan Kumar ^α, D. Srinivasa Rao ^σ, B. Pooja ^ρ, G. Harika ^ω & Y. Anil Kumar [¥]


Abstract- Triazines and chalcones are interesting class of heterocyclic compounds with a prominent structural core system present in numerous pharmacologically active compounds. It is proved from the literature that the compounds containing 1,3,5-triazine moiety or chalcone bridge often shows significant biological activity profiles. Based on these observations, it was considered worthwhile to synthesize and characterize some new 1,3,5-triazine-chalcone hybrid molecules in the present investigation. As a part of our research program aimed at search for new hybrid pharmacophores as potential cytotoxic agents, we are interested to have α,β -unsaturated ketone linker to the 1,3,5-triazine basic nucleus to give a series of 1,3,5-triazine-chalcone hybrid molecules. Therefore, in the present study an attempt has been made to synthesize and characterize various analogs of fully unsaturated 2-substituted-4,6 dichloro-1,3,5 triazine based chalcone hybrids. The chief intermediate in the present study 1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino) phenyl) ethanone was prepared by reaction between cyanuric chloride i.e. 2,4,6-trichloro-1,3,5-triazine and 3- amino acetophenone. Further, successive base catalyzed Claisen-Schmidt condensation of the compound with appropriate substituted aromatic/heteroaromatic aldehydes in the presence of 100% potassium hydroxide solution in ethanol afforded a series of 1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(substituted)-2-propen-1-ones. All the newly synthesized compounds were characterized by CHN elemental analysis and spectroscopic methods such as FT-IR, ¹H NMR, and LC mass spectral analysis.

Keywords: fully unsaturated, 1,3,5-triazine-chalcone hybrids, spectral characterization.

I. INTRODUCTION

Triazines are a class of organic nitrogen-containing six-membered heterocyclic compounds known for a long period of time. They can structurally be existing as three isomers varied with their position of nitrogen atoms on the benzene ring, and are referred to as 1,2,3-triazine (1), 1,2,4-triazine (2) and 1,3,5-triazine

(3). In particular, considerable attention has been devoted to the development of 1,3,5-triazine derivatives in comparison with 1,2,3-triazine and 1,2,4-triazine derivatives, due to their variety of applications in different fields [1,2].








1,3,5-Triazines can also be called as symmetric or s-triazines. The chemistry of this group of compounds has been studied intensively since past two centuries due to their wide spread applications in the pharmaceutical, textile, plastic and rubber industries and are used as pesticides, dyestuffs, optical bleaches, explosives and surface active agents. In recent times, several studies have been carried out on the antitumor activity of 1,3,5-triazines. Some of these analogues, hexamethylmelamine (4), almitrine (5) and irsogladine (6) are clinically used as anticancer agents. Baker triazines (4,6-Diamino-2,2-dimethyl-1,2-dihydro-1,3,5-triazine based analogs) are becoming increasingly important as pharmaceuticals. Baker triazine antifol (7) had been undergoing clinical trials as a drug candidate in cancer chemotherapy [3-8].

Author α σ : K C Reddy Institute of Pharmaceutical sciences, Jangamguntapalem, Medikonduru (Md), Guntur (Dt), A.P, India. e-mail: gunukulavenkat@gmail.com


Author ρ ω : Sims College of Pharmacy, Mangaldas Nagar, Guntur (Dt) A.P, India. e-mails: poojaboyapati2009@gmail.com, harikagunukula@gmail.com

Author $\¥$: Hindu College of Pharmacy, Amaravathi Road, Guntur (Dt), A.P, India. e-mail: anilkumaryerragopu@gmail.com



Although 1,3,5-triazines are well known in the context of anticancer drugs, this ring is also found in the drug used in the chemotherapy of malaria, as seen in case of cycloguanil (**8**) [9]. Recently, 2,4,6-trisubstituted -1,3,5-triazine scaffolds were discovered as a potent inhibitors of *M. tuberculosis* H37Rv [10].

All 1,3,5-triazine derivatives that have wide practical applications are 2,4,6-mono, di- or tri-substituted, symmetrical and nonsymmetrical compounds bearing different substituents. The most important reagent for obtaining these synthetic molecule transformations is cyanuric chloride (**9**), due to the reactivity of the chlorine atoms towards nucleophiles [11].




II. MATERIALS AND METHODS

A brief description of the solvents, chemicals procured, the instruments and the conditions employed for the characterization of the synthesized compounds are presented here. The organic solvents such as methanol, acetone, chloroform and ethyl acetate were of spectral grade and used as such without further purification. Anhydrous methanol was obtained by fractional distillation and storing over type 4A molecular sieves. The acetone present in methanol was removed by using the following procedure: A mixture of 500 mL of methanol, 25 mL of furfural and 60 ml of 10% sodium hydroxide solution was refluxed for 12 h, then the mixture was distilled and the first few milliliters of the distillate was rejected as it contains trace amount of formaldehyde. Ethanol obtained by distillation of commercial ethyl alcohol was refluxed over ignited calcium oxide for 6 h and distilled at atmospheric pressure and then used. All the major chemicals were purchased from Sigma-Aldrich. The important starting materials were procured from Sigma-Aldrich. Thin layer chromatography (TLC) was performed in the course of the reaction to optimize the reaction for purity and completion of reaction on Merck silica gel precoated GF₂₅₄ aluminum plates using mixture of different polar and nonpolar solvents in varying proportions and spots were observed using iodine as visualizing agent. Silica gel (100-200 mesh, Merck grade) has been used for

column chromatography. The column was subjected to gradient elution using n-hexane, mixtures of hexane and ethyl acetate (5%, 10%, 15%, 25%, 50% and 75% hexane in ethyl acetate), ethyl acetate and mixtures of ethyl acetate and methanol (1%, 2%, 5% and 10% ethyl acetate in methanol). Fractions each of 100 mL were collected. The separation of the compounds was checked on TLC under UV lamp and also by spraying the plates with 10% sulphuric acid in methanol.

All the melting points were determined in open capillary tubes in an EZ-MELT automated digital melting point apparatus and are uncorrected. IR spectra were recorded (in KBr) on a Perkin-Elmer FTIR. ^1H NMR and ^{13}C NMR spectra were recorded on a Bruker spectrometer at 400 MHz using TMS as the internal standard. Mass spectra (ESI) were measured on an LC-MS 6100 QQQ (Agilent Technologies, USA). Elemental analyses were carried out with Carlo Erba 1108 elemental analyzer apparatus. The results of elemental analyses (C, H, N) were within $\pm 0.4\%$ of the calculated values.



Scheme 1 : Chemical synthesis of 1,3,5-triazine-chalcone hybrid molecules 4a-4ii.

The IR spectrum of all the compounds 4a-ii exhibited the characteristic absorptions at various frequencies correspondingly at 3310-3110 and 1640-1715 cm^{-1} suggesting the presence of a secondary amine group and α,β -unsaturated carbonyl group respectively. In the ^1H NMR spectra of 1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(substituted)-2-propen-1-ones (4a-ii), a singlet integrating for one proton characteristic of the secondary amine NH group was observed in between δ 9.2-9.4 ppm as a broad signal. As seen in case of **compound 4a**, the IR spectrum of 4a exhibited characteristic $-\text{C}=\text{C}-$ (aliphatic) and $-\text{C}=\text{C}-$ (aromatic) stretching bands at

III. CHEMISTRY


The reaction sequence intended for the preparation of title compounds (4a-ii) is shown in **Scheme 1**, and their physical properties are depicted in **Tables 1** and **2**. The chief intermediate in the present study 1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino) phenyl) ethanone (3) was prepared by reaction between cyanuric chloride i.e. 2,4,6-trichloro-1,3,5-triazine (1) and 3-aminoacetophenone (2) [12]. Further, successive base catalyzed Claisen-Schmidt condensation of the compound 3 with appropriate substituted aromatic/heteroaromatic aldehydes in the presence of 100% potassium hydroxide solution in ethanol afforded a series of 1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino) phenyl)-3-(substituted)-2-propen-1-ones (4a-ii) in good yield. All the newly synthesized compounds were characterized by CHN elemental analysis and spectroscopic methods such as FT-IR, ^1H NMR, and LC mass spectral analysis. Eventually all the spectra of the new products (4a-ii) are in keeping with the predictable structures.

frequencies 1645 and 1513 cm^{-1} , respectively. The other IR absorptions at various frequencies correspondingly at 3155 and 1688 cm^{-1} suggesting the presence of a secondary amino group and α,β -unsaturated ketone group, respectively. The 400 MHz ^1H NMR spectrum of the compound 4a in $\text{DMSO}-d_6$ as solvent with TMS as an internal standard exhibited characteristic peaks of H_α and H_β protons of α,β -unsaturated ketone bridge appeared as two doublets, one doublet at δ 7.78 ppm (H_α , $J = 15.4$ Hz) and the other one at δ 8.01 ppm (H_β , $J = 15.4$ Hz). The large J value 15.4 Hz of both the protons clearly reveals the *trans* geometry at the double bond. The distinguishing peak of NH proton appears as


one singlet δ 9.74 ppm. The ESI mass spectrum (positive ion mode) of 4a revealed a $(M+H)^+$ ion at m/z 372. Based on the above spectral information the

structure of the compound 4a was confirmed as (*E*)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(phenyl)-2-propen-1-one [13-15].

Table 1 : List of new 1,3,5-triazine-chalcone hybrid molecules 4a-ii produced via Scheme 1.



Compound	R	Molecular formula	Relative Molecular Mass (g)	M.p. (°C)	Yield (%)
4a	Phenyl	C ₁₈ H ₁₂ Cl ₂ N ₄ O	371	123	60
4b	2-MeC ₆ H ₄	C ₁₉ H ₁₄ Cl ₂ N ₄ O	385	135	51
4c	3-MeC ₆ H ₄	C ₁₉ H ₁₄ Cl ₂ N ₄ O	385	143	66
4d	4-MeC ₆ H ₄	C ₁₉ H ₁₄ Cl ₂ N ₄ O	385	175	68
4e	2-OMeC ₆ H ₄	C ₁₉ H ₁₄ Cl ₂ N ₄ O ₂	401	167	71
4f	3-OMeC ₆ H ₄	C ₁₉ H ₁₄ Cl ₂ N ₄ O ₂	401	129	58
4g	4-OMeC ₆ H ₄	C ₁₉ H ₁₄ Cl ₂ N ₄ O ₂	401	145	61
4h	3-OHC ₆ H ₄	C ₁₈ H ₁₂ Cl ₂ N ₄ O ₂	387	122	74
4i	4-OHC ₆ H ₄	C ₁₈ H ₁₂ Cl ₂ N ₄ O ₂	387	161	78
4j	3,5-diOHC ₆ H ₃	C ₁₈ H ₁₂ Cl ₂ N ₄ O ₃	403	182	69
4k	4,5-diOHC ₆ H ₃	C ₁₈ H ₁₂ Cl ₂ N ₄ O ₃	403	154	51
4l	2-Me,5-OHC ₆ H ₃	C ₁₉ H ₁₄ Cl ₂ N ₄ O ₂	401	169	55
4m	2-NH ₂ C ₆ H ₄	C ₁₈ H ₁₃ Cl ₂ N ₅ O	386	154	67
4n	3-NH ₂ C ₆ H ₄	C ₁₈ H ₁₃ Cl ₂ N ₅ O	386	133	71
4o	4-NH ₂ C ₆ H ₄	C ₁₈ H ₁₃ Cl ₂ N ₅ O	386	139	68
4p	2-NO ₂ C ₆ H ₄	C ₁₈ H ₁₁ Cl ₂ N ₅ O ₃	416	120	52
4q	3-NO ₂ C ₆ H ₄	C ₁₈ H ₁₁ Cl ₂ N ₅ O ₃	416	140	77
4r	4-NO ₂ C ₆ H ₄	C ₁₈ H ₁₁ Cl ₂ N ₅ O ₃	416	124	84
4s	2-ClC ₆ H ₄	C ₁₈ H ₁₁ Cl ₃ N ₄ O	405	138	81
4t	3-ClC ₆ H ₄	C ₁₈ H ₁₁ Cl ₃ N ₄ O	405	181	71
4u	4-ClC ₆ H ₄	C ₁₈ H ₁₁ Cl ₃ N ₄ O	405	149	73
4v	2,4-diClC ₆ H ₃	C ₁₈ H ₁₀ Cl ₄ N ₄ O	440	192	59
4w	2-FC ₆ H ₄	C ₁₈ H ₁₁ Cl ₂ FN ₄ O	389	152	67
4x	3-FC ₆ H ₄	C ₁₈ H ₁₁ Cl ₂ FN ₄ O	389	132	55
4y	4-FC ₆ H ₄	C ₁₈ H ₁₁ Cl ₂ FN ₄ O	389	145	51
4z	2,4-diFC ₆ H ₃	C ₁₈ H ₁₀ Cl ₂ F ₂ N ₄ O	407	160	67
4aa	Furan-2-yl	C ₁₆ H ₁₀ Cl ₂ N ₄ O ₂	361	188	71
4bb	Thiophen-3-yl	C ₁₆ H ₁₀ Cl ₂ N ₄ OS	377	177	78
4cc	Pyrrrol-2-yl	C ₁₆ H ₁₁ Cl ₂ N ₅ O	360	121	66
4dd	Pyridin-2-yl	C ₁₇ H ₁₁ Cl ₂ N ₅ O	372	124	72
4ee	Pyridin-3-yl	C ₁₇ H ₁₁ Cl ₂ N ₅ O	372	151	79
4ff	Pyridin-4-yl	C ₁₇ H ₁₁ Cl ₂ N ₅ O	372	197	77
4gg	Naphthalen-2-yl	C ₂₂ H ₁₄ Cl ₂ N ₄ O	421	105	81
4hh	Naphthalen-3-yl	C ₂₂ H ₁₄ Cl ₂ N ₄ O	421	117	87
4ii	Anthracen-9-yl	C ₂₆ H ₁₆ Cl ₂ N ₄ O	471	220	68

Table 2 : Elemental analysis data of 1,3,5-triazine-chalcone conjugates 4a-ii produced via Scheme 1.


Compound	% Elemental analysis of C, H, N ^b					
	Calculated			Found		
	C	H	N	C	H	N
4a	58.24	3.26	15.09	58.21	3.21	15.05
4b	59.24	3.66	14.54	59.22	3.62	14.52
4c	59.24	3.66	14.54	59.25	3.61	14.53
4d	59.24	3.66	14.54	59.22	3.64	14.51
4e	56.87	3.52	13.96	56.82	3.51	13.95
4f	56.87	3.52	13.96	56.83	3.51	13.91
4g	56.87	3.52	13.96	56.84	3.56	13.96
4h	55.83	3.12	14.47	55.85	3.11	14.42
4i	55.83	3.12	14.47	55.83	3.11	14.45
4j	53.62	3.00	13.89	53.61	3.02	13.81
4k	53.62	3.00	13.89	53.61	3.04	13.82
4l	56.87	3.52	13.96	56.86	3.51	13.93
4m	55.97	3.39	18.13	55.95	3.31	18.11
4n	55.97	3.39	18.13	55.94	3.32	18.12
4o	55.97	3.39	18.13	55.93	3.35	18.14
4p	51.94	2.66	16.83	51.95	2.62	16.82
4q	51.94	2.66	16.83	51.92	2.65	16.85
4r	51.94	2.66	16.83	51.93	2.62	16.81
4s	53.29	2.73	13.81	53.21	2.71	13.82
4t	53.29	2.73	13.81	53.22	2.74	13.81
4u	53.29	2.73	13.81	53.23	2.71	13.84
4v	49.12	2.29	12.73	49.11	2.25	12.71
4w	55.55	2.85	14.39	55.53	2.82	14.35
4x	55.55	2.85	14.39	55.52	2.84	14.35
4y	55.55	2.85	14.39	55.51	2.81	14.32
4z	53.09	2.48	13.76	53.01	2.42	13.72
4aa	53.21	2.79	15.51	53.22	2.75	15.50
4bb	50.94	2.67	14.85	50.97	2.65	14.82
4cc	66.25	3.42	11.89	66.22	3.41	11.86
4dd	54.86	2.98	18.82	54.82	2.96	18.88
4ee	54.86	2.98	18.82	54.81	2.95	18.89
4ff	54.86	2.98	18.82	54.85	2.92	18.81
4gg	62.72	3.35	13.30	62.71	3.32	13.32
4hh	62.72	3.35	13.30	62.72	3.31	13.33
4ii	66.25	3.42	11.89	66.22	3.40	11.85

IV. EXPERIMENTAL SECTION

Synthesis of 1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)ethanone (3)

To a solution of 2,4,6-trichloro-1,3,5-triazine (1) (0.01 M) dissolved in 20 mL of acetone, 3-aminoacetophenone (2) (0.01 M) was added slowly by delivering through a spatula in small quantities and the resulting mixture was stirred at 0-5 °C temperature for 3h. The crude 1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)


phenyl)ethanone (3) was washed on the vacuum filter with cold methanol and then recrystallized from ethanol.

Synthesis of 1,3,5-triazine-chalcone hybrid molecules (4a-ii)

To a solution of 1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)ethanone (3) (0.005 M) and suitably substituted aldehydes (0.005 M) in ethanol (10 ml), aqueous solution of potassium hydroxide (100%) was added drop wise with continuous stirring at room temperature over a period of 10 min. The reaction

mixture was then kept at room temperature for about 48 h with occasional shaking. After 48 h it was poured into ice-cold water, and then neutralized to pH 2 using 5 N hydrochloric acid. The light yellow precipitate obtained was filtered, washed, dried, and recrystallized from dry ethanol. The 1,3,5-triazine-chalcone hybrid molecules **4a-ii** were obtained in good yield. All the synthesized compounds as mentioned in **Table 1** were characterized by spectroscopic methods such as FTIR, ^1H NMR, ^{13}C NMR and LC mass spectral analysis and presented separately under each compound.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(phenyl)-2-propen-1-one (4a):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{max} , cm^{-1}): 3155 (N-H), 3031 (C-H, aromatic), 2884 (C-H, aliphatic), 1688 (C=O), 1645 (C=C, aliphatic), 1513 (C=C, aromatic), 689 (C-Cl).

^1H NMR (400 MHz, DMSO- d_6 , δ , ppm): 7.13-7.74 (m, 9H, Ar-H), 7.78 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 8.01 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.74 (s, 1H, NH).

ESI-MS (m/z): 372 $[\text{M}+\text{H}]^+$.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(2-methylphenyl)-2-propen-1-one (4b):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{max} , cm^{-1}): 3152 (N-H), 3022 (C-H, aromatic), 2881 (C-H, aliphatic), 1689 (C=O), 1623 (C=C, aliphatic), 1501 (C=C, aromatic), 688 (C-Cl).

^1H NMR (400 MHz, DMSO- d_6 , δ , ppm): 2.32 (s, 3H, CH_3), 7.43-8.04 (m, 8H, Ar-H), 7.78 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 8.01 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.74 (s, 1H, NH).

ESI-MS (m/z): 386 $[\text{M}+\text{H}]^+$.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(3-methylphenyl)-2-propen-1-one (4c):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{max} , cm^{-1}): 3127 (N-H), 3027 (C-H, aromatic), 2777 (C-H, aliphatic), 1703 (C=O), 1603 (C=C, aliphatic), 1450 (C=C, aromatic), 688 (C-Cl).

^1H NMR (400 MHz, DMSO- d_6 , δ , ppm): 2.41 (s, 3H, CH_3), 7.38-8.05 (m, 8H, Ar-H), 7.73 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 8.04 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.69 (s, 1H, NH).

ESI-MS (m/z): 386 $[\text{M}+\text{H}]^+$.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(4-methylphenyl)-2-propen-1-one (4d):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{max} , cm^{-1}): 3122 (N-H), 3015 (C-H, aromatic), 2762 (C-H, aliphatic), 1705 (C=O), 1601 (C=C, aliphatic), 1440 (C=C, aromatic), 685 (C-Cl).

^1H NMR (400 MHz, DMSO- d_6 , δ , ppm): 2.39 (s, 3H, CH_3), 7.31-7.66 (m, 8H, Ar-H), 7.73 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 8.02 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.62 (s, 1H, NH).

ESI-MS (m/z): 386 $[\text{M}+\text{H}]^+$.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(2-methoxyphenyl)-2-propen-1-one (4e):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{max} , cm^{-1}): 3124 (N-H), 3027 (C-H, aromatic), 2975 (C-H, aliphatic), 1700 (C=O), 1603 (C=C, aliphatic), 1417 (C=C, aromatic), 713 (C-Cl), 1171 (C-O-C), 1054 (C-O).

¹H NMR (400 MHz, DMSO-d₆, δ, ppm): 3.86 (s, 3H, OCH₃), 7.20-8.05 (m, 8H, Ar-H), 7.48 (d, J = 15.2 Hz, 1H, HC=CH (H-α)), 8.05 (d, J = 15.2 Hz, 1H, HC=CH (H-β)), 9.66 (s, 1H, NH).

ESI-MS (m/z): 402 [M+H]⁺.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(3-methoxyphenyl)-2-propen-1-one (4f):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{max}, cm⁻¹): 3124 (N-H), 3027 (C-H, aromatic), 2977 (C-H, aliphatic), 1700 (C=O), 1605 (C=C, aliphatic), 1457 (C=C, aromatic), 687-(Cl), 1171 (C-O-C), 1054 (C-O).

¹H NMR (400 MHz, DMSO-d₆, δ, ppm): 3.88 (s, 3H, OCH₃), 7.12-8.21 (m, 8H, Ar-H), 7.71 (d, J = 15.2 Hz, 1H, HC=CH (H-α)), 8.06 (d, J = 15.2 Hz, 1H, HC=CH (H-β)), 9.65 (s, 1H, NH).

ESI-MS (m/z): 402 [M+H]⁺.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(4-methoxyphenyl)-2-propen-1-one (4g):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{max}, cm⁻¹): 3122 (N-H), 3021 (C-H, aromatic), 2970 (C-H, aliphatic), 1690 (C=O), 1602 (C=C, aliphatic), 1455 (C=C, aromatic), 677-(Cl), 1170 (C-O-C), 1055 (C-O).

¹H NMR (400 MHz, DMSO-d₆, δ, ppm): 3.86 (s, 3H, OCH₃), 7.12-7.92 (m, 8H, Ar-H), 7.71 (d, J = 15.2 Hz, 1H, HC=CH (H-α)), 8.05 (d, J = 15.2 Hz, 1H, HC=CH (H-β)), 9.75 (s, 1H, NH).

ESI-MS (m/z): 402 [M+H]⁺.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(3-hydroxyphenyl)-2-propen-1-one (4h):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{max}, cm⁻¹): 3445 (O-H), 3124 (N-H), 3015 (C-H, aromatic), 2984 (C-H, aliphatic), 1689 (C=O), 1606 (C=C, aliphatic), 1415 (C=C, aromatic), 676 (C-Cl), 1054 (C-O).

¹H NMR (400 MHz, DMSO-d₆, δ, ppm): 7.36-8.01 (m, 8H, Ar-H), 7.67 (d, J = 15.6 Hz, 1H, HC=CH (H-α)), 8.18 (d, J = 15.6 Hz, 1H, HC=CH (H-β)), 9.85 (s, 1H, NH), 12.32 (s, 1H, OH).

ESI-MS (m/z): 388 [M+H]⁺.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(4-hydroxyphenyl)-2-propen-1-one (4i):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{max}, cm⁻¹): 3444 (O-H), 3124 (N-H), 3019 (C-H, aromatic), 2982 (C-H, aliphatic), 1684 (C=O), 1602 (C=C, aliphatic), 1412 (C=C, aromatic), 671 (C-Cl), 1055 (C-O).

¹H NMR (400 MHz, DMSO-d₆, δ, ppm): 7.16-7.62 (m, 8H, Ar-H), 7.68 (d, J = 15.6 Hz, 1H, HC=CH (H-α)), 8.14 (d, J = 15.6 Hz, 1H, HC=CH (H-β)), 9.82 (s, 1H, NH), 12.31 (s, 1H, OH).

ESI-MS (m/z): 388 [M+H]⁺.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(3,5-dihydroxyphenyl)-2-propen-1-one (4j):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{max}, cm⁻¹): 3440 (O-H), 3122 (N-H), 3027 (C-H, aromatic), 2890 (C-H, aliphatic), 1700 (C=O), 1605 (C=C, aliphatic), 1511 (C=C, aromatic), 688 (C-Cl), 1054 (C-O).

¹H NMR (400 MHz, DMSO-d₆, δ, ppm): 7.21-8.02 (m, 7H, Ar-H), 7.79 (d, J = 15.3 Hz, 1H, HC=CH (H-α)), 8.03 (d, J = 15.3 Hz, 1H, HC=CH (H-β)), 9.89 (s, 1H, NH), 11.52 (s, 2H, OH).

ESI-MS (m/z): 404 [M+H]⁺.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(4,5-dihydroxyphenyl)-2-propen-1-one (4k):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{max} , cm^{-1}): 3395 (O–H), 3127 (N–H), 3017 (C–H, aromatic), 2989 (C–H, aliphatic), 1686 (C=O), 1615 (C=C, aliphatic), 1545 (C=C, aromatic), 689 (C–Cl), 1054 (C–O).

1H NMR (400 MHz, DMSO- d_6 , δ , ppm): 7.55–8.03 (m, 7H, Ar-H), 7.83 (d, $J = 15.3$ Hz, 1H, HC=CH (H- α)), 8.08 (d, $J = 15.3$ Hz, 1H, HC=CH (H- β)), 9.58 (s, 1H, OH), 9.87 (s, 1H, NH), 10.57 (s, 1H, OH).

ESI-MS (m/z): 404 [M+H] $^+$.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(2-methyl-5-hydroxyphenyl)-2-propen-1-one (4l):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{max} , cm^{-1}): 3440 (O–H), 3122 (N–H), 3021 (C–H, aromatic), 2975 (C–H, aliphatic), 1690 (C=O), 1641 (C=C, aliphatic), 1486 (C=C, aromatic), 678 (C–Cl), 1054 (C–O).

1H NMR (400 MHz, DMSO- d_6 , δ , ppm): 2.47 (s, 3H, CH $_3$), 7.62–8.01 (m, 7H, Ar-H), 7.81 (d, $J = 15.3$ Hz, 1H, HC=CH (H- α)), 8.08 (d, $J = 15.3$ Hz, 1H, HC=CH (H- β)), 9.01 (s, 1H, NH), 10.52 (s, 1H, OH).

ESI-MS (m/z): 402 [M+H] $^+$.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(2-aminophenyl)-2-propen-1-one (4m):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{max} , cm^{-1}): 3367 (NH $_2$), 3117 (N–H), 2978 (C–H, aromatic), 2763 (C–H, aliphatic), 1693 (C=O), 1597 (C=C, aliphatic), 1413 (C=C, aromatic), 688 (C–Cl), 1296 (C–N).

1H NMR (400 MHz, DMSO- d_6 , δ , ppm): 7.74–8.11 (m, 8H, Ar-H), 7.58 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 8.06 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.65 (s, 1H, NH), 10.51 (s, 2H, Ar-NH $_2$).

ESI-MS (m/z): 387 [M+H] $^+$.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(3-aminophenyl)-2-propen-1-one (4n):



Colour: Light yellow crystals.

FT-IR (KBr, ν_{max} , cm^{-1}): 3367 (NH $_2$), 3117 (N–H), 2978 (C–H, aromatic), 2763 (C–H, aliphatic), 1693 (C=O), 1597 (C=C, aliphatic), 1413 (C=C, aromatic), 688 (C–Cl), 1290 (C–N).

1H NMR (400 MHz, DMSO- d_6 , δ , ppm): 7.72 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 7.74–8.11 (m, 8H, Ar-H), 8.01 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.67 (s, 1H, NH), 10.54 (s, 2H, Ar-NH $_2$).

ESI-MS (m/z): 387 [M+H] $^+$.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(4-aminophenyl)-2-propen-1-one (4o):

Colour: Light yellow crystals.


FT-IR (KBr, ν_{max} , cm^{-1}): 3362 (NH $_2$), 3115 (N–H), 2979 (C–H, aromatic), 2761 (C–H, aliphatic), 1690 (C=O), 1590 (C=C, aliphatic), 1410 (C=C, aromatic), 684 (C–Cl), 1290 (C–N).

1H NMR (400 MHz, DMSO- d_6 , δ , ppm): 7.71 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 7.77–8.14 (m, 8H, Ar-H), 8.12 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.65 (s, 1H, NH), 10.52 (s, 2H, Ar-NH $_2$).

ESI-MS (m/z): 387 [M+H] $^+$.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-

(2-nitrophenyl)-2-propen-1-one (4p):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{\max} , cm^{-1}): 3122 (N-H), 3024 (C-H, aromatic), 2776 (C-H, aliphatic), 1700 (C=O), 1604 (C=C, aliphatic), 1414 (C=C, aromatic), 688-(Cl), 1529 (N=O), 1291 (C-N).

$^1\text{H NMR}$ (400 MHz, DMSO-d_6 , δ , ppm): 6.86-8.18 (m, 8H, Ar-H), 8.05 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 8.35 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.72 (s, 1H, NH).

ESI-MS (m/z): 417 $[\text{M}+\text{H}]^+$.

(*E*)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(3-nitrophenyl)-2-propen-1-one (4q):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{\max} , cm^{-1}): 3115 (N-H), 3026 (C-H, aromatic), 2775 (C-H, aliphatic), 1700 (C=O), 1599 (C=C, aliphatic), 1412 (C=C, aromatic), 688-(Cl), 1522 (N=O), 1290 (C-N).

$^1\text{H NMR}$ (400 MHz, DMSO-d_6 , δ , ppm): 7.55-8.39 (m, 8H, Ar-H), 7.86 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 8.06 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.73 (s, 1H, NH).

ESI-MS (m/z): 417 $[\text{M}+\text{H}]^+$.

(*E*)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(4-nitrophenyl)-2-propen-1-one (4r):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{\max} , cm^{-1}): 3205 (N-H), 3016 (C-H, aromatic), 2895 (C-H, aliphatic), 1710 (C=O), 1589 (C=C, aliphatic), 1442 (C=C, aromatic), 680 (C-Cl), 1520 (N=O), 1287 (C-N).

$^1\text{H NMR}$ (400 MHz, DMSO-d_6 , δ , ppm): 7.54-8.29 (m, 8H, Ar-H), 7.83 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 8.07 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.23 (s, 1H, NH).

ESI-MS (m/z): 417 $[\text{M}+\text{H}]^+$.

(*E*)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(2-chlorophenyl)-2-propen-1-one (4s):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{\max} , cm^{-1}): 3127 (N-H), 3027 (C-H, aromatic), 2893 (C-H, aliphatic), 1689 (C=O), 1597 (C=C, aliphatic), 1450 (C=C, aromatic), 688-(Cl), 786 (C-Cl).

$^1\text{H NMR}$ (400 MHz, DMSO-d_6 , δ , ppm): 7.60 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 7.62-8.24 (m, 8H, Ar-H), 7.78 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.65 (s, 1H, NH).

ESI-MS (m/z): 406 $[\text{M}+\text{H}]^+$.

(*E*)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(3-chlorophenyl)-2-propen-1-one (4t):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{\max} , cm^{-1}): 3121 (N-H), 3025 (C-H, aromatic), 2891 (C-H, aliphatic), 1686 (C=O), 1594 (C=C, aliphatic), 1451 (C=C, aromatic), 786 (C-Cl).

$^1\text{H NMR}$ (400 MHz, DMSO-d_6 , δ , ppm): 7.45 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 7.62-7.74 (m, 8H, Ar-H), 7.79 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.65 (s, 1H, NH).

ESI-MS (m/z): 406 $[\text{M}+\text{H}]^+$.

(*E*)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(4-chlorophenyl)-2-propen-1-one (4u):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{\max} , cm^{-1}): 3126 (N-H), 3023 (C-H, aromatic), 2883 (C-H, aliphatic), 1690 (C=O), 1588 (C=C, aliphatic), 1442 (C=C, aromatic), 681 (C-Cl), 785 (C-Cl).

$^1\text{H NMR}$ (400 MHz, DMSO-d_6 , δ , ppm): 7.61 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 7.67-7.82 (m, 8H, Ar-H), 7.87 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.63 (s, 1H, NH).

ESI-MS (m/z): 406 $[\text{M}+\text{H}]^+$.

(*E*)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(2,4-dichlorophenyl)-2-propen-1-one (4v):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{\max} , cm^{-1}): 3124 (N-H), 3018 (C-H, aromatic), 2891 (C-H, aliphatic), 1689 (C=O), 1641 (C=C, aliphatic), 1485 (C=C, aromatic), 691 (C-Cl), 786 (C-Cl).

$^1\text{H NMR}$ (400 MHz, DMSO-d_6 , δ , ppm): 7.65-8.23 (m, 7H, Ar-H), 7.78 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 8.06 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.69 (s, 1H, NH).

ESI-MS (m/z): 441 $[\text{M}+\text{H}]^+$.

(*E*)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(2-fluorophenyl)-2-propen-1-one (4w):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{\max} , cm^{-1}): 3117 (N-H), 3017 (C-H, aromatic), 2977 (C-H, aliphatic), 1693 (C=O), 1605 (C=C, aliphatic), 1415 (C=C, aromatic), 688 (C-Cl), 1116 (C-F).

$^1\text{H NMR}$ (400 MHz, DMSO-d_6 , δ , ppm): 7.36-8.03 (m, 8H, Ar-H), 7.55 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 7.82 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.68 (s, 1H, NH).

ESI-MS (m/z): 390 $[\text{M}+\text{H}]^+$.

(*E*)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(3-fluorophenyl)-2-propen-1-one (4x):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{\max} , cm^{-1}): 3112 (N-H), 3011 (C-H, aromatic), 2974 (C-H, aliphatic), 1690 (C=O), 1602 (C=C, aliphatic), 1412 (C=C, aromatic), 680 (C-Cl), 1011 (C-F).

$^1\text{H NMR}$ (400 MHz, DMSO-d_6 , δ , ppm): 7.16-7.73 (m, 8H, Ar-H), 7.75 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 7.81 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.78 (s, 1H, NH).

ESI-MS (m/z): 390 $[\text{M}+\text{H}]^+$.

(*E*)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(4-fluorophenyl)-2-propen-1-one (4y):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{\max} , cm^{-1}): 3114 (N-H), 3212 (C-H, aromatic), 2975 (C-H, aliphatic), 1694 (C=O), 1602 (C=C, aliphatic), 1412 (C=C, aromatic), 1106 (C-Cl), 685 (C-Cl).

$^1\text{H NMR}$ (400 MHz, DMSO-d_6 , δ , ppm): 7.22-7.63 (m, 8H, Ar-H), 7.65 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 7.82 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.77 (s, 1H, NH).

ESI-MS (m/z): 390 $[\text{M}+\text{H}]^+$.

(*E*)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(2,4-difluorophenyl)-2-propen-1-one (4z):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{max} , cm^{-1}): 3122 (N-H), 3021 (C-H, aromatic), 2884 (C-H, aliphatic), 1693 (C=O), 1605 (C=C, aliphatic), 1415 (C=C, aromatic), 688-(Cl), 1114 (C-F).

1H NMR (400 MHz, DMSO- d_6 , δ , ppm): 7.39-8.31 (m, 7H, Ar-H), 7.76 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 8.08 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.69 (s, 1H, NH).

ESI-MS (m/z): 408 [M+H] $^+$.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(furan-2-yl)-2-propen-1-one (4aa):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{max} , cm^{-1}): 3420 (N-H), 3062 (C-H, aromatic), 3030 (C-H, aliphatic), 1671(C=O), 1591 (C=C, aliphatic), 1453 (C=C, aromatic), 696 (C-Cl), 1155 (C-O-C), 1053 (C-O).

1H NMR (400 MHz, DMSO- d_6 , δ , ppm): 6.74 (s, 1H, Ar-H), 6.21 (m, 1H, Ar-H), 7.16-7.50 (m, 5H, Ar-H), 7.62 (d, $J = 16$ Hz, 1H, HC=CH (H- α)), 8.06 (d, $J = 16$ Hz, 1H, HC=CH (H- β)), 9.73 (s, 1H, NH).

ESI-MS (m/z): 362 [M+H] $^+$.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(thiophen-3-yl)-2-propen-1-one (4bb):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{max} , cm^{-1}): 3430 (N-H), 3019 (C-H, aromatic), 2973 (C-H, aliphatic), 1689 (C=O), 1599 (C=C, aliphatic), 1414 (C=C, aromatic), 688 (C-Cl).

1H NMR (400 MHz, DMSO- d_6 , δ , ppm): 6.68 (s, 1H, Ar-H), 6.91 (s, 1H, Ar-H), 7.12 (s, 1H, Ar-H), 7.33-7.58 (m, 4H, Ar-H), 7.76 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 8.02 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.68 (s, 1H, NH).

ESI-MS (m/z): 378 [M+H] $^+$.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(pyrrol-2-yl)-2-propen-1-one (4cc):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{max} , cm^{-1}): 3144 (N-H), 3052 (N-H), 3017 (C-H, aromatic), 2973 (C-H, aliphatic), 1695 (C=O), 1615 (C=C, aliphatic), 1414 (C=C, aromatic), 678 (C-Cl), 1308 (C-N).

1H NMR (400 MHz, DMSO- d_6 , δ , ppm): 6.46 (s, 1H, Ar-H), 7.44 (m, 1H, Ar-H), 7.55-7.61 (m, 5H, Ar-H), 7.76 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 8.03 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.64 (s, 1H, NH), 10.55 (s, 1H, NH).

ESI-MS (m/z): 361 [M+H] $^+$.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(pyridin-2-yl)-2-propen-1-one (4dd):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{max} , cm^{-1}): 3127 (N-H), 3019 (C-H, aromatic), 2931 (C-H, aliphatic), 1689 (C=O), 1604 (C=C, aliphatic), 1417 (C=C, aromatic), 688 (C-Cl), 1308 (C-N).

1H NMR (400 MHz, DMSO- d_6 , δ , ppm): 6.98 (d, $J = 16$ Hz, 1H, HC=CH (H- α)), 7.13-7.69 (m, 8H, Ar-H), 7.78 (d, $J = 16$ Hz, 1H, HC=CH (H- β)), 9.60 (s, 1H, NH).

ESI-MS (m/z): 373 [M+H] $^+$.

(E)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(pyridin-3-yl)-2-propen-1-one (4ee):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{\max} , cm^{-1}): 3122 (N-H), 3011 (C-H, aromatic), 2922 (C-H, aliphatic), 1679 (C=O), 1609 (C=C, aliphatic), 1422 (C=C, aromatic), 1308 (C-N), 681 (C-Cl).

$^1\text{H NMR}$ (400 MHz, DMSO-d_6 , δ , ppm): 7.22 (d, $J = 16$ Hz, 1H, HC=CH (H- α)), 7.23-7.59 (m, 8H, Ar-H), 7.68 (d, $J = 16$ Hz, 1H, HC=CH (H- β)), 9.58 (s, 1H, NH).

ESI-MS (m/z): 373 $[\text{M}+\text{H}]^+$.

(*E*)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(pyridin-4-yl)-2-propen-1-one (4ff):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{\max} , cm^{-1}): 3127 (N-H), 3019 (C-H, aromatic), 2931 (C-H, aliphatic), 1689 (C=O), 1604 (C=C, aliphatic), 1417 (C=C, aromatic), 688 (C-Cl), 1308 (C-N).

$^1\text{H NMR}$ (400 MHz, DMSO-d_6 , δ , ppm): 6.98 (d, $J = 16$ Hz, 1H, HC=CH (H- α)), 7.13-7.69 (m, 8H, Ar-H), 7.78 (d, $J = 16$ Hz, 1H, HC=CH (H- β)), 9.60 (s, 1H, NH).

ESI-MS (m/z): 373 $[\text{M}+\text{H}]^+$.

(*E*)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(naphthalen-2-yl)-2-propen-1-one (4gg):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{\max} , cm^{-1}): 3102 (N-H), 3015 (C-H, aromatic), 2926 (C-H, aliphatic), 1684 (C=O), 1602 (C=C, aliphatic), 1416 (C=C, aromatic), 682 (C-Cl).

$^1\text{H NMR}$ (400 MHz, DMSO-d_6 , δ , ppm): 7.62-7.83 (m, 11H, Ar-H), 7.87 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 8.16 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.70 (s, 1H, NH).

ESI-MS (m/z): 422 $[\text{M}+\text{H}]^+$.

(*E*)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(naphthalen-3-yl)-2-propen-1-one (4hh):




Colour: Light yellow crystals.

FT-IR (KBr, ν_{\max} , cm^{-1}): 3115 (N-H), 3019 (C-H, aromatic), 2931 (C-H, aliphatic), 1689 (C=O), 1604 (C=C, aliphatic), 1417 (C=C, aromatic), 688 (C-Cl).

$^1\text{H NMR}$ (400 MHz, DMSO-d_6 , δ , ppm): 7.62-8.33 (m, 11H, Ar-H), 7.89 (d, $J = 15.2$ Hz, 1H, HC=CH (H- α)), 8.26 (d, $J = 15.2$ Hz, 1H, HC=CH (H- β)), 9.71 (s, 1H, NH).

ESI-MS (m/z): 422 $[\text{M}+\text{H}]^+$.

(*E*)-1-(3-(4,6-dichloro-1,3,5-triazin-2-ylamino)phenyl)-3-(anthracen-9-yl)-2-propen-1-one (4ii):



Colour: Light yellow crystals.

FT-IR (KBr, ν_{\max} , cm^{-1}): 3127 (N-H), 3019 (C-H, aromatic), 2931 (C-H, aliphatic), 1689 (C=O), 1604 (C=C, aliphatic), 1417 (C=C, aromatic), 688 (C-Cl).

$^1\text{H NMR}$ (400 MHz, DMSO-d_6 , δ , ppm): 6.98-7.41 (m, 13H, Ar-H), 7.59 (d, $J = 15.6$ Hz, 1H, HC=CH (H- α)), 8.06 (d, $J = 15.6$ Hz, 1H, HC=CH (H- β)), 9.75 (s, 1H, NH).

ESI-MS (m/z): 472 $[\text{M}+\text{H}]^+$.

V. ACKNOWLEDGEMENTS

The author is thankful to KC Reddy Institute of Pharmaceutical Sciences, Jangamguntapalem, Medikonduru, Guntur District for availing the facilities of Research laboratory, text- and e-journal access in their library sections.

REFERENCES RÉFÉRENCES REFERENCIAS

1. Ohsawa A.; Arai H.; Ohnishi H.; Igeta H. *J. Chem. Soc., Chem. Commun.*, **1981**, 1174.
2. Grzegorz, B. *Tetrahedron*. **2006**, 62, 9507.
3. Kim K. H.; Dietrich S. W.; Hansch C.; Dolnick B. J.; Bertino J. R. *J. Med. Chem.* **1980**, 23, 1248.
4. Blaney J. M.; Hansch C.; Silipo C.; Vittoria A. *Chem. Rev.* **1984**, 84, 333.
5. Foster B.J.; Harding B.J. Leyland-Jones B.; Hoth D. *Cancer Treat. Rev.* **1986**, 38, 197.
6. Labrid C.; Regnier G. L.; Laubie M. *Eur. J. Respir. Dis.* **1983**, 64 (Suppl. 126), 185
7. Ono M.; Kawahara N.; Goto D.; Wakabayashi Y.; Ushiro S.; Yoshida S.; Izumi H.; Kuwano M.; Sato Y. *Cancer Res.* **1996**, 56(7), 1512.
8. Baker B. R.; Ashton W. T. *J. Med. Chem.* **1973**, 16, 209.
9. Sirawaraporn W.; Sathitkul T.; Sirawaraporn R.; Yuthavong, Y.; Santi D. V. *Proc. Natl. Acad. Sci.* **1997**, 94, 1124.
10. Patel, R. V.; Kumari, P.; Rajani, D. P.; Chikhaliya, K. H. *Eur. J. of Med. Chem.* **2011**, 46, 4354.
11. Thurston J. T.; Schaefer F. C.; Dudley J. R; Holm-Hansen D. Illuminati G. *J. Am. Chem. Soc.* **1951**, 73, 2992..
12. Patel, R. V.; Kumari, P.; Rajani, D. P.; Chikhaliya, K. H. *Eur. J. Med. Chem.* **2011**, 46, 4354-4365.
13. Somayajulu, N.; Divakara, L.; Kasapu, V. V. V. S.; Rao, A.; Bugata, B.; Yenupuri, S. *Eur. J. Chem.* **2014**, 5(1), 144-149.
14. Bugata, B.; Krishna, K.; Satya, V.; Avupati, V. R.; Gavalapu, V.; Somayajulu, N.; Divakara, L.; Barla, S. *Eur. J. Chem.* **2013**, 4(4), 396-401.
15. Raval, J. P. *Eur. J. Chem.* **2011**, 2(3), 388-393.



GLOBAL JOURNALS INC. (US) GUIDELINES HANDBOOK 2016

WWW.GLOBALJOURNALS.ORG